Wellington Management Group
OVID icon

Wellington Management Group’s Ovid Therapeutics OVID Stock Holding History

Wellington Management Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-115,832
Closed -$89.1K – 1997
2024
Q2 		$89.1K Sell
115,832
-107,061
-48% -$298K ﹤0.01% 1871
2024
Q1 		$680K Buy
+222,893
New +$746K ﹤0.01% 1767

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group's OVID Position: Q3 2024 in Review

Wellington Management Group sold out of Ovid Therapeutics (OVID) in Q3 2024, closing a stake of 115,832 shares — an estimated $89.1K sold.

Wellington Management Group first reported a position in OVID in Q1 2024 and held it in 2 quarters. The position peaked at $680K in Q1 2024. 75 funds tracked by Wall St. Rank hold OVID as of Q3 2024.

  • Wellington Management Group reported no remaining Ovid Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wellington Management Group sold 115,832 Ovid Therapeutics shares in Q3 2024, an estimated $89.1K.
  • Wellington Management Group first reported a position in Ovid Therapeutics in Q1 2024 and held it in 2 quarters.
  • Wellington Management Group's Ovid Therapeutics position peaked at $680K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2024.

Based on Wellington Management Group's 13F filing for Q3 2024, filed 14 Nov 2024.